



REMARKS

Applicants choose the invention of Group I for examination in this application without traverse. Group I, as defined by the Examiner comprises Claim 1 - 4 and 10 drawn to a compound of Formula I classified in Class 548 and numerous subclasses.

Applicants respectfully point out that Claim 5, drawn to a series of specific compounds falls within the scope of Claims 1 - 4 and thus should be examined in conjunction with the invention of Group I. Specifically, Claim 1 claims a compound of Formula I:



The elected compound, below, is of the formula:



Thus, Applicants respectfully submit that a claim to a compound of Formula I reads on the elected species when R¹ is 4,4-difluorocyclohexyl)methyl, R² is *tert*-butyl, R³ is *n*-butyl, and R⁴ is methyl. Further, Applicants point out that the definitions of R¹, R², R³ and R⁴ in claims 1, 2, 3 and 4 encompass the species recited in Claim 5. Thus even though Claim 5 is presented as an independent claims it is within the scope of the invention of Group I.

Applicants elect the species *N*-{2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}-*N*-methylbutane-1-sulfonamide for examination in this application. The claims that read on *N*-{2-*tert*-Butyl-1-[(4,4-difluorocyclohexyl)methyl]-1*H*-benzimidazol-5-yl}-*N*-methylbutane-1-sulfonamide are Claims 1, 2, 3, 4, 5 and 10.

Application No. 10/573,054
Response to restriction requirement,
November 6, 2009

Fees:

Applicants believe no fees are required for filing this response. However, any necessary fees may be charged to deposit account 260166 and any overpayment credited to that account.

Conclusion:

Applicants solicit prompt examination on the merits.

Respectfully submitted,

Dated: November 6, 2009

By: / Kenneth F. Mitchell /
Kenneth F. Mitchell, Ph.D., J.D.
Attorney for Applicants
Reg. No. 42,007
Telephone: 302/886-7466